Welcome to our dedicated page for ODYSSEY GROUP INTL news (Ticker: ODYY), a resource for investors and traders seeking the latest updates and insights on ODYSSEY GROUP INTL stock.
Odyssey Health Inc. (OTCOB:ODYY), formerly known as Odyssey Group International, Inc., is a medical company specializing in life-enhancing medical products, with a focus on developing unique pharmaceutical treatments. The company's lead drug candidate, ONP-002, is a fully synthetic neurosteroid designed to treat moderate traumatic brain injury. With a mission to create, acquire, and develop innovative assets and technologies that offer meaningful medical solutions, Odyssey Health is at the forefront of advancing clinical utility and market opportunities. Their recent partnership with Syneos Health demonstrates their commitment to pursuing excellence and success in the medical field.
Rhea-AI Summary
Odyssey Health, Inc. (ODYY) reports $13.2 million in net income and $8.7 million in total stockholder equity for the quarter ended January 31, 2024. The increase is attributed to the sale of neurological assets to Oragenics, Inc. The company received eight million shares of Oragenics Series F preferred stock, enhancing its balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
-
Rhea-AI Summary
Odyssey Health, Inc. (OTCQB:ODYY) announces the closing of an Asset Purchase Agreement with Oragenics, Inc. (OGEN:NYSE American) for the acquisition of Odyssey's proprietary assets related to its neurological drug therapy platform. The agreement includes cash payments, issuance of preferred stock, and collaboration for the development of drug candidates for treating concussion and Niemann Pick Disease Type C. Odyssey's lead drug candidate, ONP-002, has shown promising results in preclinical and Phase 1 human clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
-
Rhea-AI Summary
Odyssey Health, Inc. (OTCOB:ODYY) received stockholder approval for the sale of its neurological drug platform technology to Oragenics, Inc. at a Special Meeting on December 7, 2023. The asset purchase agreement includes a $1,000,000 consideration, with $500,000 already received and an additional $500,000 payment upon the successful proxy vote. Odyssey will also receive eight million shares of Oragenics Convertible Preferred Class F stock. The transaction is expected to close before the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
Rhea-AI Summary
Odyssey Health, Inc. (OTCQB:ODYY) selects Syneos Health® to support its Investigational New Drug (IND) Application for its lead drug candidate ONP-002, targeting mild Traumatic Brain Injury (mTBI). Syneos Health will provide guidance and review of pre-clinical and clinical data, as well as support for the Phase II clinical trial design in the US. The partnership aims to position the study for success by leveraging Syneos Health's expertise and regulatory affairs solutions (GRAS) for neurological drugs and intranasal devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
-
Rhea-AI Summary
Odyssey Health, Inc. (OTCQB:ODYY) will hold a webcast on November 16, 2023, to provide an update on the company, recap its progress, and discuss the sale of the neurological technology platform to Oragenics, Inc. Participants can join via web link or phone. The company will receive 8 million shares of Oragenics, Inc. Series F Preferred convertible stock as part of the asset purchase agreement. The Special Meeting related to the sale will be held on December 7, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
-
Rhea-AI Summary
Odyssey Health provides an update on its Asset Purchase Agreement with Oragenics
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.65%
Tags
Rhea-AI Summary
Oragenics to acquire Odyssey Health's assets related to neurological drug therapies and technologies, including drug candidates for treating mild traumatic brain injury and Niemann Pick Disease Type C, as well as a proprietary powder formulation and nasal delivery device. The transaction includes $1.0 million in cash payments and eight million shares of Oragenics' Series F Convertible Preferred Stock. The deal is expected to close in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.71%
Tags
-
Rhea-AI Summary
Odyssey Health, Inc. (OTCQB: ODYY) has commenced trading on the OTCQB Market after up-listing from the OTC Pink Market. The up-listing expands the audience of investors that can invest in the company. Odyssey is focused on developing nasal delivery of proprietary compounds to treat neurological disorders, including mTBI. The company aims to drive enhanced clinical efficacy from its products and create shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.86%
Tags
-
Rhea-AI Summary
Odyssey Health, Inc. presented at the Military Health System Research Symposium (MHSRS) on their novel pharmaceutical, ONP-002, for brain-targeted delivery in mild traumatic brain injury (mTBI). The poster included positive preclinical data and safety findings from Phase I clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.96%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.47%
Tags
FAQ
What is the current stock price of ODYSSEY GROUP INTL (ODYY)?
The current stock price of ODYSSEY GROUP INTL (ODYY) is $0.03 as of September 27, 2024.
What is the market cap of ODYSSEY GROUP INTL (ODYY)?
The market cap of ODYSSEY GROUP INTL (ODYY) is approximately 4.2M.
What is Odyssey Health Inc. focused on developing?
Odyssey Health Inc. is focused on developing unique, life-enhancing medical products, with a specific emphasis on creating pharmaceutical treatments for various medical conditions.
What is the lead drug candidate of Odyssey Health Inc.?
The lead drug candidate of Odyssey Health Inc. is ONP-002, a fully synthetic neurosteroid being developed to treat moderate traumatic brain injury.
What is the corporate mission of Odyssey Health Inc.?
The corporate mission of Odyssey Health Inc. is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions.
What recent partnership has Odyssey Health Inc. entered into?
Odyssey Health Inc. recently partnered with Syneos Health, a leading biopharmaceutical solutions organization, to support its Investigational New Drug (IND) Application for their lead drug candidate, ONP-002.
What recent achievements has Odyssey Health Inc. reported?
Odyssey Health Inc. reported net income of $13.2 million for the quarter ended January 31, 2024, due to the sale of its neurological assets to Oragenics, Inc. The company continues to grow and develop its medical portfolio.
How can I stay updated on Odyssey Health Inc.'s news and developments?
You can visit Odyssey Health Inc.'s website or follow their corporate social media accounts on Twitter, Facebook, LinkedIn, and YouTube for the latest updates and information.
ODYSSEY GROUP INTL INC